Amylyx(AMLX) - 2024 Q3 - Quarterly Results

Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results Exhibit 99.1 • On track to initiate a Phase 3 program for Company's lead asset avexitide, a GLP-1 receptor antagonist with FDA Breakthrough Therapy and Orphan Drug Designations, in post-bariatric hypoglycemia (PBH) in the first quarter of 2025 • Reported positive topline data from Phase 2 HELIOS clinical trial of AMX0035 in Wolfram syndrome demonstrating improvement or stabilization across all disease measures at Week 24 and sustained impro ...